C4 Therapeutics Profit Margin

C4 Therapeutics (CCCC) currently reports a profit margin of 552.75% as of March 2026. That compares with -831.87% in the prior-year period — up 166.4% year over year. That is above the Healthcare sector average of 14.34%. Use the charts on this page to explore C4 Therapeutics's profit margin history and peer comparisons.

C4 Therapeutics's profit margin increased from -831.87% to 552.75% — a 166.4% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

C4 Therapeutics's profit margin of 552.75% is higher than the Healthcare sector average of 14.34%. That is roughly 3753.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but C4 Therapeutics's current 552.75% should be judged against Healthcare norms (sector average: 14.34%) and against CCCC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 552.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 14.34%. From there, open related valuation or income-statement pages for C4 Therapeutics, and consider following CCCC for alerts when major investors trade the stock.